1Karsa M,Dalla Pozza L,Venn NC,et al.Improving the identification of high risk precursor B acute lymphoblastic leukemia patients with earlier quantification of minimal residual disease[J].PLoS One,2013,8(10):e76455.
2Pui CH,Mullighan CG,Evans WE,et al.Pediatric acute lymphoblastic leukemia:where are we going and how do we get there?[J].Blood,2012,120:1165-1174.
3Flohr T,Schrauder A,Cazzaniga G,et al.Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOPBFM ALL 2000for childhood acute lymphoblastic leukemia[J].Leukemia,2008,22:771-782.
4Ratei R,Basso G,Dworzak M,et al.Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000protocol with multiparameter flow cytometry:predictive impact of early blast reduction on the remission status after induction[J].Leukemia,2008,23:528-534.
